

**MATERIALS LICENSE**

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

|  |   |   |
|--|---|---|
| <p style="text-align: center;"><b>Licensee</b></p> <p>1. Trinity Health - Michigan<br/>d/b/a St. Mary Mercy Hospital</p> <p>2. 36475 W Five Mile Rd.<br/>Livonia, MI 48154</p> | <p>In accordance with letter dated March 26, 2019,</p> <p>3. License number: 21-14849-01 is amended in its entirety to read as follows:</p> | <p>4. Expiration Date: July 31, 2024</p> <p>5. Docket No.: 030-08159<br/>Reference No.:</p> |
|--|---|---|

| 6. Byproduct, source, and/or special nuclear material | 7. Chemical and/or physical form                            | 8. Maximum amount that licensee may possess at any one time under this license | 9. Authorized use  |
|---|---|--|--|
| A. Any byproduct material permitted by 10 CFR 35.100  | A. Any  | A. As Needed   | A. For use in uptake, dilution and excretion studies permitted by 10 CFR 35.100. |
| B. Any byproduct material permitted by 10 CFR 35.200  | B. Any  | B. As Needed   | B. For use in imaging and localization studies permitted by 10 CFR 35.200.       |
| C. Any byproduct material permitted by 10 CFR 35.300  | C. Any  | C. 2 curies total, not to exceed 1 curie of iodine-131                         | C. For any use permitted by 10 CFR 35.300.                                       |
| D. Iridium-192 permitted by 10 CFR 35.400             | D. Sealed Sources (Best Medical International, Model 81-01) | D. 1 curie total   | D. For any manual brachytherapy procedure permitted by 10 CFR 35.400.            |

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License Number  
21-14849-01

Docket or Reference Number  
030-08159

Amendment No. 63

- | 6. Byproduct, source, and/or special nuclear material | 7. Chemical and/or physical form   | 8. Maximum amount that licensee may possess at any one time under this license | 9. Authorized use   |
|---|--|--|---|
| E. Iodine-125 permitted by 10 CFR 35.400              | E. Sealed Sources (Bard Brachytherapy, Model STM-1251; Best Medical International, Model 2301; IsoAid, LLC., Model IAI-125A (Advantage E125); Medi-Physics, Inc., Model 6733 (EchoSeed); North American Scientific, Model MED3631; Theragenics, Model AgX 100) | E. 1 curie total   | E. For any manual brachytherapy procedure permitted by 10 CFR 35.400. |
| F. Palladium-103 permitted by 10 CFR 35.400           | F. Sealed Sources (Best Medical International, Model 2335; North American Scientific, Model MED3633; Theragenics, Model TS200)   | F. 1 curie total   | F. For any manual brachytherapy procedure permitted by 10 CFR 35.400. |
| G. Cesium-131 permitted by 10 CFR 35.400              | G. Sealed Sources (IsoRay, Model CS-1)   | G. 1 curie total   | G. For any manual brachytherapy procedure permitted by 10 CFR 35.400. |
| H. Any byproduct material permitted by 10 CFR 31.11   | H. Prepackaged Kits  | H. 2 millicuries total   | H. For use in in-vitro studies.                                       |

**CONDITIONS**

10. Licensed material may be used or stored at the licensee's facilities located at 36475 W Five Mile Rd., Livonia, Michigan, 48154.
11. The Radiation Safety Officer (RSO) for this license is Nader Mohtadi, M.D.

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License Number  
21-14849-01

Docket or Reference Number  
030-08159

Amendment No. 63

12. Licensed material shall only be used by, or under the supervision of:

A. Individuals permitted to work as authorized users in accordance with 10 CFR 35.13 and 10 CFR 35.14.

B. The following individuals are authorized users for the material and medical uses as indicated:

| <u>Authorized User(M.D.,D.O.,etc.)</u> | <u>Material and Use</u>  |
|--|--|
| Ramin B. Behjatnia, D.O.               | 10 CFR 35.100,10 CFR 35.200; 10 CFR 35.300 (limited to oral administration of sodium iodide I-131) |
| James Paul Carl, M.D.                  | 10 CFR 35.100,10 CFR 35.200,10 CFR 35.300  |
| Christopher Markus Eshaki, M.D.        | 10 CFR 35.100,10 CFR 35.200  |
| Stephanie E. Falbo, M.D.               | 10 CFR 35.100,10 CFR 35.200,10 CFR 35.300  |
| George Henning, M.D.                   | 10 CFR 35.300; 10 CFR 35.400   |
| Karen Lee Johnson-Haddlesey, M.D.      | 10 CFR 35.100,10 CFR 35.200  |
| Nader Mohtadi, M.D.                    | 10 CFR 35.100,10 CFR 35.200,10 CFR 35.300  |
| Samir Narayan, M.D.                    | 10 CFR 35.400  |
| Walter M. Sahjidak, M.D.               | 10 CFR 35.300; 10 CFR 35.400   |
| Sean Theisen, M.D.                     | 10 CFR 35.100,10 CFR 35.200  |


**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**License Number  
21-14849-01Docket or Reference Number  
030-08159

Amendment No. 63

13. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

A. Application dated February 3, 2014 (ML14037A449)

B. Letter dated June 12, 2017 (ML17180A513)



FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date: May 29, 2019

By: \_\_\_\_\_

*Colleen Carol Casey*  
Colleen Carol Casey  
Region 3